This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Preventing Hypotension in Parturients With an Elevated Body Mass Index (BMI)

This study has been completed.
Sponsor:
Collaborator:
Duke University
Information provided by (Responsible Party):
Ronald George, IWK Health Centre
ClinicalTrials.gov Identifier:
NCT01481740
First received: July 22, 2011
Last updated: September 14, 2016
Last verified: September 2016
July 22, 2011
September 14, 2016
November 2010
December 2014   (Final data collection date for primary outcome measure)
  • Incidence of Nausea and Vomiting [ Time Frame: intraoperative ]
  • Incidence of Nausea and Vomiting [ Time Frame: 2 hrs postoperative ]
  • Incidence of Nausea and Vomiting [ Time Frame: 24hrs postoperative ]
Incidence of Nausea and Vomiting [ Time Frame: intraoperative, 2 hrs postoperative, 24hrs postoperative ]
Complete list of historical versions of study NCT01481740 on ClinicalTrials.gov Archive Site
  • Incidence of Hypotension [ Time Frame: intraoperative - predelivery ]
  • Incidence of Hypotension [ Time Frame: intraoperative - postdelivery ]
  • Neonatal Acidosis [ Time Frame: intraoperative ]
  • Incidence of Hypotension [ Time Frame: intraoperative ]
  • Neonatal Acidosis [ Time Frame: intraoperative ]
Not Provided
Not Provided
 
Preventing Hypotension in Parturients With an Elevated Body Mass Index (BMI)
A Double Blind Randomized Controlled Trial of Phenylephrine for the Prevention of Spinal Induced Hypotension in Obese Parturients
Previous research regarding the use of phenylephrine has excluded obese subjects (BMI >35). This subgroup of patients represents a large portion of the obstetric patient population locally and nationally. It is unclear whether previous research should be extrapolated to the obese patient population. This study is being done to compare the incidence of hypotension, intraoperative nausea and vomiting, and neonatal acidosis between obese patients who receive a prophylactic phenylephrine infusion versus those who receive phenylephrine boluses for the treatment of established hypotension. This study will help us determine whether using a phenylephrine infusion or a phenylephrine bolus is the best way to prevent/treat spinal induced hypotension during cesarean deliveries in obese patients.
Not Provided
Interventional
Phase 4
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Hypotension
  • Drug: Phenylephrine bolus
    10 ml of 100mcg/ml phenylephrine and placebo infusion
  • Drug: phenylephrine infusion
    60ml infusion of 100mcg/ml phenylephrine and placebo bolus
  • Experimental: Phenylephrine bolus
    Intervention: Drug: Phenylephrine bolus
  • Experimental: Phenylephrine infusion
    Intervention: Drug: phenylephrine infusion
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
170
December 2014
December 2014   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • English speaking
  • ASA Physical Status I-II
  • Non-laboring women
  • Single gestations ≥ 36 weeks
  • Obese women (Body Mass Index 35 - 55 kg/m2)
  • Non-emergent CD under spinal anesthesia

Exclusion Criteria:

  • Height < 5'0"
  • Antiemetic drug use in the 24 hours prior to CD
  • Allergy to phenylephrine, or any other standardized medication
  • Hypertensive disease of pregnancy (i.e. mild & severe preeclampsia)
  • Chronic hypertension receiving antihypertensive treatment
  • Severe Cardiac disease in pregnancy with marked functional limitations
  • Patients on Monoamine Oxidase Inhibitors or Tricyclic Antidepressants
  • Subject enrollment in another study involving a study medication within 30 days of CD
  • Any other physical or psychiatric condition which may impair their ability to cooperate with study data collection
Sexes Eligible for Study: Female
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Canada,   United States
 
 
NCT01481740
4999-01460
Yes
Not Provided
Not Provided
Ronald George, IWK Health Centre
IWK Health Centre
Duke University
Principal Investigator: Ronald B George, MD FRCPC IWK Health Centre
IWK Health Centre
September 2016

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP